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ABSTRACT
Objective: To establish whether HIV disease is associated with abnormal levels of age-related
brain atrophy, by estimating apparent brain age using neuroimaging and exploring whether these
estimates related to HIV status, age, cognitive performance, and HIV-related clinical parameters.
Methods: A large sample of virologically suppressed HIV-positive adults (n 5 162, age 45–82
years) and highly comparable HIV-negative controls (n 5 105) were recruited as part of the Co-
morbidity in Relation to AIDS (COBRA) collaboration. Using T1-weighted MRI scans, a machine-
learning model of healthy brain aging was defined in an independent cohort (n 5 2,001, aged 18–
90 years). Neuroimaging data from HIV-positive and HIV-negative individuals were then used to
estimate brain-predicted age; then brain-predicted age difference (brain-PAD 5 brain-predicted
brain age 2 chronological age) scores were calculated. Neuropsychological and clinical assess-
ments were also carried out.
Results: HIV-positive individuals had greater brain-PAD score (mean 6 SD 2.15 6 7.79 years)
compared to HIV-negative individuals (20.876 8.40 years; b5 3.48, p, 0.01). Increased brain-
PAD score was associated with decreased performance in multiple cognitive domains (informa-
tion processing speed, executive function, memory) and general cognitive performance across all
participants. Brain-PAD score was not associated with age, duration of HIV infection, or other
HIV-related measures.
Conclusion: Increased apparent brain aging, predicted using neuroimaging, was observed in
HIV-positive adults, despite effective viral suppression. Furthermore, the magnitude of increased
apparent brain aging related to cognitive deficits. However, predicted brain age difference did not
correlate with chronological age or duration of HIV infection, suggesting that HIV disease may
accentuate rather than accelerate brain aging. Neurology® 2017;88:1–9
GLOSSARY
Brain-PAD 5 brain-predicted age difference; cART 5 combination antiretroviral therapy; COBRA 5 Comorbidity in Relation
to AIDS; FOV5 field of view;GM5 gray matter; ICV5 intracranial volume;MAE5mean absolute error;MNI1525Montreal
Neurological Institute 152; RMSE 5 root mean squared error; TE 5 echo time; TR 5 repetition time; WM 5 white matter.
Despite effective viral suppression due to combination antiretroviral therapy (cART), chronic HIV
disease has been linked with a higher risk of multiple diseases of old age. These include cardiovas-
cular, renal, hepatic, or pulmonary disease, cancer, osteoporosis, and physical frailty.1–4 This has
led researchers to consider whether chronic HIV disease accelerates the normal aging process,5
a hypothesis potentially supported by the increased prevalence of cognitive impairment.6–8 If HIV
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accelerates cognitive aging, this has huge impli-
cations for HIV-positive individuals, their fam-
ilies, and the health care systems tasked with
providing future care.
Cognitive aging is a consequence of physio-
logic changes in the brain (i.e., brain aging),
including a loss of brain volume.9 Deviations
from a typical brain-aging trajectory (e.g., accel-
eration) may result from a brain injury, neuro-
degenerative disease, or, potentially, chronic
HIV. While reduced brain volumes are fre-
quently reported in HIV disease,10–19 the evi-
dence supporting accelerated brain aging is
more equivocal.10,20,21 These studies used mac-
roscopic brain volume measures to correlate
with chronological age. In contrast, we em-
ployed machine learning to make explicit
estimations of age, based on 3D brain volume
maps.22 Such neuroimaging-based brain age
estimations appear sensitive to pathologic as-
pects of aging and cognitive impairment,22–24
thus representing a potential biomarker of brain
aging.
Here, we generated brain-predicted age dif-
ference (brain-PAD) scores in HIV-positive in-
dividuals and highly comparable HIV-negative
controls, testing the following hypotheses: (1)
HIV-positive individuals would have greater
brain-PAD than HIV-negative individuals; (2)
brain-PAD would be associated with deficits
in cognitive performance; (3) HIV-related pa-
rameters would be associated with brain-PAD.
METHODS Participants. The study included 162 HIV-
positive individuals and 105 HIV-negative controls who had
highly similar demographic and lifestyle characteristics (table 1).
These participants comprised the test set in the machine-learning
analysis. Participants were recruited from 2 sites, London and
Amsterdam, as part of the Comorbidity in Relation to AIDS
(COBRA) collaboration. Exclusion criteria for COBRA were as
follows: age under 45 years, current major depression (Patient
Health Questionnaire–9 score of $15), confounding neurologic
diseases, previous severe head injury (loss of consciousness
$30 minutes), previous cerebral infections (including AIDS-
defining CNS diseases), self-reported IV drug use within the last
6 months, daily use of recreational drugs (with the exception of
cannabis), excess alcohol intake (.48 units per week), severe
psychiatric disease, or MRI contraindications. All HIV-positive
participants were required to be on cART and to have had
undetectable plasma HIV RNA (,50 copies/mL) for $12
months prior to enrollment.
A further 2,001 individuals (1,016 male, mean 6 SD age
36.956 18.12 years; range 18–90) comprised the training dataset.
These individuals were drawn from publicly available data reposi-
tories (table e-1 at Neurology.org) and were screened according to
each study’s local inclusion protocols to ensure the absence of
neurologic or psychiatric diseases and major health conditions.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the institutional review
board of the Academic Medical Center and the London (Stan-
more) Research Ethics Committee. All participants gave written
informed consent. For participants comprising the training
dataset, ethical approval was granted for each contributing study
and permission for subsequent data sharing was verified for each
data repository.
Neuropsychological assessment. Participants completed
a comprehensive neuropsychological assessment, with tests of atten-
tion, executive function, language fluency, memory, speed of infor-
mation processing, and motor function (table e-2). Raw test scores
were standardized as t scores (age-, sex-, and education level–
adjusted). Higher t scores represented better cognitive function.
Test scores were averaged within domains to calculate domain-
specific t scores and across domains to calculate a global t score.
Three HIV-positive participants were missing data for one or more
domains. Categorical classifications of cognitive impairment in
HIV were made based on the global deficit score.25 The global
deficit score is obtained by converting cognitive domain t scores
to deficit scores and then averaging them. A score$0.5 was defined
as cognitively impaired.
Table 1 Characteristics of HIV-positive and HIV-negative study participants
HIV-positive HIV-negative p Value
No. 162 105
Age, y 56 (50.9–62.0) 55.8 (50.1–62.0) 0.87
Sex 0.97
Female 9 (5.6) 6 (5.7)
Male 153 (94.4) 99 (94.3)
Study site 0.14
Amsterdam 103 (63.6) 76 (72.4)
London 58 (36.4) 29 (27.6)
Years of education 14 (13–16) 16 (14–16) 0.31
Smoking status 0.10
Current smoker 47 (29.0) 25 (23.8)
Ex-smoker 72 (44.4) 39 (37.1)
Never smoked 43 (26.5) 41 (39.0)
Alcohol consumption (units per week) 5.5 (1.5–15.0) 5.5 (1.5–15.0) 0.66
Use of recreational drugs in last 6 mo 53 (32.7) 26 (25.0) 0.17
CD41 count, cells/mL 622 (472–809.8) —
CD41:CD81 cell count ratio 0.8 (0.60–1.1) —
Nadir CD41 count, cells/mL 170 (90–250) —
Time since HIV diagnosis, y 14.6 (9.2–19.3) —
Duration of antiretroviral therapy, y 12.6 (7.5–16.8) —
Time with CD41 < 500 cells/mm3, mo 150.9 (65.0–246.1) —
Prior clinical AIDS 56 (34.6) —
Hepatitis B infection 7 (4.3) 0 (0.0)
Hepatitis C infection 14 (8.6) 1 (1.0)
Syphilis infection 13 (8.0) 2 (1.9)
Values are shown as median (interquartile range) or n (%). p Refers to group comparison
Wilcoxon rank-sum or Fisher exact tests where appropriate.
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Neuroimaging data acquisition. Acquisition parameters were
harmonized between sites and scanners (London: Siemens [Mu-
nich, Germany] Verio 3T; Amsterdam: Philips [Best, the Nether-
lands] Intera, upgraded to Ingenia 3T). This resulted in the
following protocols for 3D T1-weighted structural images:
London: magnetization-prepared rapid gradient-echo, echo time
(TE) 2.98 ms, repetition time (TR) 2,300 ms, inversion time
900 ms, flip angle 98, field of view (FOV) 256 mm, 160 slices of
1.0 mm thickness, in-plane resolution 1.03 1.0 mm; Amsterdam:
sagittal turbo field echo, TE 3.1 ms, TR 6.6 ms, flip angle 98, FOV
270mm, 170 slices of 1.2 mm thickness, in-plane resolution 1.13
1.1 mm. Three-dimensional structural images for the training set
were acquired using various parameters and field strengths (1.5T
and 3T), according to local study protocols (table e-1).
Brain age prediction procedure. An overview of the brain
age prediction procedure is presented in figure 1. We followed
the protocol as previously outlined,22 with the minor adaptation
that gray matter (GM) and white matter (WM) images were
analyzed together, to generate a whole-brain predicted age,
rather than tissue-specific age predictions. In brief, all images
were preprocessed using SPM12 (University College London,
UK) to generate normalized 3D maps of GM and WM volume,
in Montreal Neurological Institute 152 (MNI152) space.
Normalization used SPM-DARTEL for nonlinear registration
and resampling included modulation and 4-mm smoothing.
Information from 4 individuals was excluded at this stage (1
HIV-positive, 3 HIV-negative) due to excess motion artefact or
poor head positioning, resulting in a final sample size of 161
HIV-positive and 102 HIV-negative participants for the test
set, alongside 2,001 individuals in the training set.
Brain age prediction was carried out by defining a Gaussian
processes regression to model the relationship between 3D GM
and WM volume maps and chronological age in the training
set, using PRoNTo v2.0 (mlnl.cs.ucl.ac.uk/pronto). Age predic-
tions on all participants were generated using 10-fold cross-
validation. Model accuracy was expressed as the correlation
between age and predicted age (Pearson r), total variance ex-
plained (R2), mean absolute error (MAE), and root mean squared
error (RMSE). The statistical significance of this model was as-
sessed using permutation testing (n 5 1,000).
Coefficients from the validated regression model were then
applied to the test data (i.e., HIV-positive and HIV-negative
individuals). This generated a brain-predicted age estimate per
participant. Finally, brain-PAD scores were calculated for each
test participant by subtracting chronological age from brain-
predicted age. Hence, a positive brain-PAD indicates that the
participant’s brain was predicted to be older than his or her
chronological age. Brain-PAD scores were used in subsequent
analysis to index age-adjusted, or relative, brain aging.
As neuroimaging data were acquired on multiple scanners,
a separate sample of healthy volunteers were scanned in both Lon-
don and Amsterdam (n 5 11, age range 23–42 years) to assess
between-scanner reliability. Brain-PAD scores were calculated for
each participant from scans at both sites. The absolute agreement
of brain-PAD score between scanners was high; intraclass corre-
lation coefficient 5 0.95, 95% confidence interval 0.84–0.99,
p , 0.01.
Statistical analysis. Further statistical analyses were conducted
using R, v3.2.3. With brain-PAD scores as the dependent
variable, HIV-positive and HIV-negative groups were compared
using a linear regression. Covariates included scanner type, sex,
intracranial volume (ICV), and smoking status, but not age. For
analysis of neuropsychological performance, linear regression
models were fit using domain t scores as the dependent
variable, and brain-PAD score, HIV status, sex, and ICV as
predictor variables. Interactions between HIV-status and brain-
PAD score were then modeled by repeating the above linear
regressions with the addition of an interaction term. Multiple
comparison correction across the 6 domains was not carried out
due to the non-independent nature of the neuropsychological
tests. Effect sizes for linear regression were quantified using
partial h2. Group differences in categorical variables (e.g.,
smoking status, sex, cognitive impairment) were assessed using
Fisher exact tests. Group comparisons in neuropsychological test
performance were performed using the Wilcoxon rank-sum test.
RESULTS Age can be accurately predicted using
neuroimaging data. Cross-validation in the training
set indicated that data from 3D brain volume maps
accurately predicted chronological age in the training
set (r 5 0.94, R2 5 0.88, MAE 5 5.01, RMSE 5
6.31; figure 2). This remained significant after per-
mutation correction (corrected p , 0.01).
Brain-predicted age difference is higher in HIV-positive
individuals. HIV-positive individuals showed increased
brain-PAD (brain-predicted age 2 chronological age)
scores, compared to HIV-negative individuals (b 5
3.31, SE 5 1.0, t 5 3.30, p , 0.01, h2 5 0.031;
figure 3A). Mean brain-PAD score in HIV-positive
individuals was 2.15 (SD 7.79) years, while in HIV-
negative individuals it was20.87 (SD 8.4) years. HIV-
positive individuals’ brain-PAD scores were greater
than the training set mean (i.e., brain-PAD of 0)
(t 5 3.51, p , 0.01), while HIV-negative
individuals’ brain-PAD scores were not (t 5 21.05,
p 5 0.3). Brain-predicted age correlated with
chronological age in both groups (HIV-positive: r 5
0.75, p , 0.01; HIV-negative: r 5 0.69, p , 0.01;
figure 3B). Importantly, there was no interaction
between age and group in predicting brain-PAD
(p 5 0.28), indicating that the association with HIV
disease did not vary as a function of chronological age.
HIV-positive individuals show evidence of impaired
cognitive performance. HIV-positive individuals showed
impaired neuropsychological performance relative to
HIV-positive controls in multiple cognitive domains.
These were as follows: attention (W 5 10,683.5, p ,
0.01), processing speed (W 5 10,674.5, p , 0.01),
executive function (W 5 10,004.5, p 5 0.01) and
motor function (W 5 9,874, p 5 0.02), alongside
global cognitive performance (W 5 10,499.5, p ,
0.01). For language fluency (p 5 0.30) and memory
(p 5 0.38), t scores did not differ between HIV-
positive and HIV-negative groups. Global deficit score
categorization showed that cognitive impairment was
more common in the HIV-positive group compared to
HIV-negative controls (number cognitively impaired:
HIV-positive 5 31 [19.1%], HIV-negative 5 6
[5.7%], odds ratio 3.92 [95% confidence interval
1.53–11.94], p , 0.01).
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Figure 1 Study methods
Outline of machine learning brain age prediction methods used in the study. Data included 3 separate groups: healthy individuals (n5 2,001) comprised the
training data, and HIV-positive individuals (n5 161) and HIV-negative controls (n5 102) comprised the test data, after quality control (n5 4 exclusions). (A)
Continued
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Brain-predicted age difference correlates with cognitive
performance. Brain-PAD related to cognitive perfor-
mance across HIV-positive and HIV-negative
participants. Brain-PAD was inversely associated
with performance in the domains of information
processing speed, executive function, and memory,
and with global cognitive performance (table 2).
Trend-level associations were evident for attention,
language, and motor function (0.05 , p , 0.1).
Interactions between HIV status and brain-PAD
were not significant for any cognitive domain (p .
0.1), indicating that the influence of brain-PAD on
cognitive performance did not vary according to
HIV-status. Brain-PAD score did not differ based
on global deficit score categorization of cognitive
impairment (p . 0.1), either when grouping all
participants together or when looking solely within
HIV-positive individuals.
Associations with HIV-related factors.HIV-related clin-
ical measures were generally unrelated to brain-PAD
score in HIV-positive individuals (all p . 0.1).
These included years since HIV diagnosis, duration
of cART, nadir CD4 count, months spent with CD4
count ,500 cells/mL, current CD4 count, current
CD8 count, and CD4:CD8 ratio or a prior
diagnosis of AIDS. We also assessed whether factors
such as a history of hepatitis B or C infection, syphilis,
cigarette smoking (pack-years), and recreational drug
use within 6 months influenced brain-PAD in HIV-
positive individuals; however, no associations were
evident (all p . 0.1).
DISCUSSION Increased levels of age-associated
changes to brain structure were evident in HIV-
positive individuals with suppressed plasma HIV
viremia, compared to a highly comparable HIV-
negative group. The magnitude of increased brain
aging (i.e., brain-PAD score), derived from structural
neuroimaging, related to neuropsychological test
scores. Individuals with older brain-predicted ages,
relative to chronological age, showed deficits in
information processing speed, executive function,
memory, and global cognitive performance. Brain-
PAD score did not correlate with chronological age or
duration of infection, suggesting that HIV disease does
not accelerate the rate of age-associated brain atrophy.
Increased brain-PAD was associated with poorer
cognitive performance in multiple domains. The char-
acteristic pattern of age-related cognitive decline is asso-
ciated with impairments in processing speed, executive
function, and memory, while vocabulary and general
knowledge are thought to be relatively stable.26 The
largest effect sizes for a relationship with brain-PAD
score were found for memory, executive function,
and processing speed, similar to the expected pattern
of typical cognitive aging. However, at least borderline
effects were seen in all domains and the strength of
these associations was relatively modest. This means
that we cannot definitively conclude whether changes
in brain-PAD score relate specifically to cognitive aging
or more general cognitive impairment. Moreover, cog-
nitive performance between domains is likely to be
interrelated, potentially driven by information process-
ing speed,27 or general intelligence. Interestingly, the
relationship between brain-PAD and cognitive perfor-
mance was seen in both HIV-positive and HIV-
negative groups, despite observing greater cognitive
impairment in HIV-positive individuals. This implies
that brain-PAD reflects a general relationship between
brain structure and cognition. HIV is potentially accen-
tuating these age-related changes in brain structure,
which then drives deficits in cognitive performance.
That the damage to the brain in HIV relates to that
seen in normal aging agrees with previous work that has
reported a spatial overlap between HIV-associated
brain regions and regions associated with aging and
cognitive performance in both HIV-positive and
HIV-negative individuals.11 Hence, it is plausible that
chronic HIV disease could be driving atrophy in brain
regions that commonly change with advancing age,
resulting in deficits in cognitive performance.
Our results suggest that chronic HIV disease may
cause abnormal brain aging, which could be either
accelerated or accentuated.28 Accelerated aging implies
an interaction with aging that progressively increases
the risk of age-related morbidity, while accentuated
aging implies that some initial process increased the
burden of aging-related damage but remains static over
time. Our findings favor the latter interpretation, as we
found no relationship between brain-PAD score and
chronological age or duration of HIV diagnosis. This
fits with evidence from neuroimaging studies that have
Figure 1 legend, continued:
All data were preprocessed with statistical parametric mapping (SPM) to segment T1 images into gray matter (GM) and white matter (WM) images. These
segmented images were then normalized to a custom template using DARTEL for nonlinear registration, before being resampled to Montreal Neurological
Institute 152 (1.5 mm3) template space, using volumetric modulation and a 4-mm smoothing kernel. GM and WM images were then concatenated for each
subject. (B) Machine learning age prediction used PRoNTo. (a) Representation of all data in a linear kernel form as a similarity matrix of the dot products
between pairs of vectorized and concatenated volume images. (b) Supervised learning stage. Data from the training set were run through a Gaussian
processes regression model to define the correspondence between brain volume maps and chronological age. Model accuracy was assessed on predictions
made during a 10-fold cross-validation procedure. (c) Test set prediction. The coefficients from the model trained on the healthy sample were used to
generate predicted age values from the data in the HIV-positive individuals and HIV-negative controls. Brain-predicted age difference (brain-PAD) scores
were defined by subtracting chronological age from predicted age. (C) Statistical analysis based on brain-PAD scores as an index of apparent brain aging.
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demonstrated independent effects of aging and HIV
on the brain,10,11,16,19,29 and does not support reports of
accelerating effects.12,21,30 However, these previous
studies often included a preponderance of untreated
individuals, those with detectable HIV viremia, or
younger adults (i.e., ,50 years old). These findings
are difficult to extrapolate to older, well-treated HIV-
positive populations, where the effects of aberrant
aging will be more pertinent. Furthermore, inferences
regarding duration of HIV diagnosis as a proxy of
duration of actual HIV infection must be made cau-
tiously when date of seroconversion is unknown.
Clinical parameters relating to HIV were not asso-
ciated with brain-PAD. Previous research has associ-
ated nadir CD4 count14,15 and duration of known
HIV infection13,17 with measures of brain structure,
although not universally.10,16,19 The nature of the par-
ticipants in these studies differs substantively from
ours. In general, HIV-positive individuals in our
study were older, and all were effectively treated with
cART and had higher CD4 counts. Crucially, our
HIV-negative control group was recruited to be
highly comparable, reducing the influence of impor-
tant confounding factors such as cigarettes, alcohol,
and recreational drug use. The lack of association
with current HIV-related parameters indicates that
when viral replication is suppressed, such factors
may have limited ongoing relevance to brain health.
Neuroimaging-based age predictions may represent
a biomarker of the aging process. Such measures could
potentially track neurodegeneration in the aging HIV-
positive population and identify those at greater risk for
poor cognitive outcomes. Cellular and molecular
markers of biological aging have also indicated age-
like increases in HIV, using telomere length, markers
of CD8 T-cell senescence and DNA methylation lev-
els.31–35 Our findings generally concur with these re-
ports, which suggests that individuals with chronic
HIV disease also experience increased accumulation
of the cellular damage associated with aging, resulting
in age-like brain atrophy. HIV-positive individuals
were on average more than 3 years older compared
to the control group. This is a lower estimate compared
to age predictions from the epigenetic clock, where
brain tissue and blood resulted in 7.4 and 5.2 years
of increased aging, respectively.32 Whether this is due
to differences in the methods or the characteristics of
the HIV-positive individuals is unclear. A major con-
sideration of DNA-based aging biomarkers is the type
of cells used to derive the estimates. T cells, for exam-
ple, may well have been affected by the presence of
HIV. Brain age and DNA methylation age prediction
methods are conceptually similar and it would be of
interest to compare age predictions made using DNA
methylation profiles and structural neuroimaging. Fur-
thermore, integrating multiple sources of molecular,
cellular, and physiologic data could provide highly
informative insights into distinct compartments of bio-
logical aging or improve estimates of a more global
biological age measure. Accurate aging biomarkers
have great potential for detecting heightened risks of
age-associated diseases in HIV-positive individuals and
may aid in the design and recruitment of clinical trials
of treatments aimed at reducing the burden of comor-
bid disease.
We observed lower brain volumes in HIV-positive
individuals, presumably due to atrophy. Our model
allows us to quantify this change and relate it to brain
structure in healthy individuals. HIV-positive indi-
viduals had brains that resembled individuals 2.15
years older. We interpret this as increased brain aging,
although one must be cautious in interpreting the re-
sults in this way. Brain atrophy does not necessarily
mean aging per se. For example, neurologic insults
(e.g., stroke, focal lesions from a traumatic brain
injury, encephalitis) can result in brain tissue loss that
is not primarily due to aging. However, our partici-
pants were free from a history of cerebral infections
or focal neurologic injury. Hence, gross insults are
unlikely to be driving the results. The observed brain
Figure 2 Brain-predicted age in the training dataset
Scatterplot of chronological age (x-axis) and predicted brain age (y-axis), based on results of
10-fold cross-validation of the Gaussian processes regression model in the training dataset
(n5 2,001). Dashed line (black) represents the line of identity (y5 x), where predicted age 5
chronological age.
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tissue loss is likely to be the result of historical damage
or the gradual buildup of deleterious factors, such as
persistent neuroinflammation. It is unclear whether
the biological mechanisms underlying brain tissue
loss in HIV are the same as the mechanisms involved
in brain aging. However, what is evident at the mac-
roscopic level we have studied (i.e., volumetric MRI)
is that the HIV brain appears prematurely aged.
Our study has further limitations. One is the cross-
sectional design employed. Longitudinal studies are
necessary for examining individual-specific trajectories
of brain aging36 to properly evaluate evidence for accel-
erated aging. Also, brain-PAD showed high variability,
indicating that it is potentially noise-prone. However,
as ground truth brain age is unobtainable, this variation
could be either measurement error or meaningful
interindividual variability. However, high between-
scanner reliability (intraclass correlation coefficient
0.95) and correlations with cognitive performance
and other real-world measures in this and previous
studies22 support the use of such a measure to index
age-related changes to brain structure. Other limita-
tions are that our sample predominantly included
white, northern European men. HIV is a global pan-
demic, thus corroboration of increased brain age in
HIV in other populations is important.37 Individuals
in the training dataset used in the current study were
generally not explicitly screened for HIV infection,
though all were assessed to be cognitively normal and
free of potentially confounding conditions. Undiag-
nosed rates of HIV are low (,1%), so this would have
been unlikely to confound the results. Also, we did not
investigate other HIV-related factors not directly asso-
ciated with the virus that could also affect brain aging,
such as antiretroviral toxicity, lifestyle, and cardiovas-
cular disease.38 Finally, our machine learning method
benefits from using a large independent normative
database, where the relationship between 3D brain
volume maps and age is modeled across the adult life-
span. However, HIV disease may result in specific
Table 2 Brain-predicted age difference (brain-PAD) and neuropsychological
assessments
Cognitive domain
Main effect of brain-PAD
Brain-PAD by
HIV-status
interaction
b SE t p Value h2 (90% CI) t p Value
Processing speed 20.13 0.06 22.25 0.03 0.019 (0.0–0.06) 0.73 0.46
Executive function 20.15 0.06 22.48 0.01 0.023 (0.0–0.07) 0.17 0.87
Language 20.13 0.07 21.88 0.06 0.014 (0.0–0.05) 0.48 0.64
Memory 20.20 0.06 23.32 ,0.01 0.041 (0.01–0.08) 1.04 0.30
Attention 20.14 0.08 21.71 0.09 0.011 (0.0–0.04) 0.56 0.58
Motor function 20.11 0.06 21.73 0.09 0.012 (0.0–0.05) 1.20 0.23
Global cognition 20.14 0.04 23.33 ,0.01 0.040 (0.01–0.09) 1.03 0.31
Abbreviations: b 5 unstandardized regression coefficient; CI 5 confidence interval; h2 5
partial h2 effect size estimate; SE 5 standard error.
Results shown are from separate linear regression models with brain-PAD score as the
outcome variable and each cognitive domain t score as the predictor variable.
Figure 3 Predicted age differences in HIV infection
(A) Grouped data plot of brain-predicted age difference (brain-PAD) in HIV-positive individuals (red triangles) and HIV-negative controls (blue spots). Solid
black lines indicate group mean brain-PAD values. (B) Scatterplot of chronological age in years (x-axis) against predicted brain age (y-axis) generated using
structural neuroimaging. Points indicate HIV-positive individuals (red triangles) and HIV-negative controls (blue spots) and lines are regression lines for each
group (HIV-positive 5 red; HIV-negative 5 blue), with 95% confidence intervals displayed. Dashed gray line is the line of identity (y 5 x).
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brain changes that are not captured by this model and
may explain some of the observed cognitive deficits.
For instance, treated HIV has been associated with
microstructural WM abnormalities39 and WM hyper-
intensities40 that would not be detected by our model.
Future studies could incorporate further imaging
modalities to better model differential patterns of brain
aging in HIV.
HIV-positive individuals with undetectable plasma
HIV RNA showed increased brain age, estimated using
structural neuroimaging. This increase in apparent
brain age related to neuropsychological performance
across multiple cognitive domains, indicating that
brain-predicted age may tap into aspects of cognitive
aging, a major risk factor for negative long-term out-
comes in older adults with HIV disease. However,
chronological age was not associated with the magni-
tude of increased brain age. Thus our results are more
consistent with the idea of accentuated, rather than
accelerated, brain aging in treated HIV disease.
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